Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.080
-0.020 (-1.82%)
At close: Dec 5, 2025, 4:00 PM EST
1.071
-0.009 (-0.81%)
After-hours: Dec 5, 2025, 7:40 PM EST
Fate Therapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Fate Therapeutics stock ranges from a low of $2.00 to a high of $7.00. The average analyst price target of $3.92 forecasts a 262.96% increase in the stock price over the next year.
Price Target: $3.92 (+262.96%)
Analyst Consensus: Buy
* Price targets were last updated on Oct 31, 2025.
Analyst Ratings
The average analyst rating for Fate Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 2 | 1 | 1 | 2 | 2 | 2 |
| Hold | 6 | 6 | 6 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +362.96% | Oct 31, 2025 |
| Wedbush | Wedbush | Hold → Buy Upgrades $5 → $7 | Hold → Buy | Upgrades | $5 → $7 | +548.15% | Oct 27, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Oct 27, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $4 → $2.5 | Hold | Maintains | $4 → $2.5 | +131.48% | Aug 13, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 12, 2025 |
Financial Forecast
Revenue This Year
6.48M
from 13.63M
Decreased by -52.48%
Revenue Next Year
4.82M
from 6.48M
Decreased by -25.54%
EPS This Year
-1.17
from -1.64
EPS Next Year
-1.17
from -1.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 8.2M | 10.5M | ||||
| Avg | 6.5M | 4.8M | ||||
| Low | 5.2M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -39.9% | 62.1% | ||||
| Avg | -52.5% | -25.5% | ||||
| Low | -62.1% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.16 | -0.96 | ||||
| Avg | -1.17 | -1.17 | ||||
| Low | -1.16 | -1.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.